As healthcare systems and institutional hospital groups navigate unsustainable expenditures for biological oncology therapies, biosimilars have become the definitive solution to reconcile clinical efficacy with long-term fiscal sustainability. Monoclonal antibodies targeting HER2 (trastuzumab) and CD20 (rituximab) remain fundamental backbone therapies for breast cancer, gastric cancer, and non-Hodgkin lymphomas. However, originators and early-generation alternatives often strain hospital pharmacy budgets. Headquartered in Shanghai, Henlius Biotech (复宏汉霖) set global industry benchmarks by engineering Trastuzumab Biosimilar (HLX02 / Zercepac® / 汉曲优®) and Rituximab Biosimilar (HLX01 / Hanlikang® / 汉利康®) under European Union Good Manufacturing Practice (EU GMP) standards.
For international health ministries, hospital procurement boards, oncology group purchasing organizations (GPOs), and pharmaceutical distributors seeking to source high-volume, European-approved oncology biosimilars, China Medical Concierge – Shanghai (CMCS) provides authoritative on-ground procurement navigation and clinical liaison services in Shanghai.
1. Clinical Bioequivalence & Landmark International Registrations
Henlius's biosimilars are built on rigorous physicochemical characterization, advanced structural analytics, and head-to-head global Phase 3 equivalence clinical trials:
Trastuzumab Biosimilar (HLX02 / Zercepac®): The EU-Approved Dual-Indication Benchmark
- First Chinese Biosimilar Authorized in the European Union: Approved by both the European Commission (EC) and China NMPA, Zercepac® is commercialized across major European markets—including the United Kingdom, Germany, France, and Spain—as well as across Latin America and Asia-Pacific.
- Global Head-to-Head Equivalence: Demonstrated clinical bioequivalence, identical pharmacokinetics, safety profiles, and low immunogenicity compared to originator Herceptin in multinational Phase 3 trials involving HER2-positive breast cancer and gastric cancer cohorts.
- Therapeutic Indications: HER2-overexpressing early and metastatic breast cancer; HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction.
- Flexible Dosing Formulations: Engineered in multiple dosage strengths (e.g., 60 mg, 150 mg preservative-free vials) to optimize individualized weight-based patient dosing and reduce hospital pharmacy reconstitution waste.
Rituximab Biosimilar (HLX01 / Hanlikang®): The Pioneer in Lymphoma Care
- First Domestically Approved Biosimilar in China: Engineered to match reference MabThera/Rituxan across all structural, functional, and clinical dimensions.
- Hematologic Oncology Indications: CD20-positive Diffuse Large B-Cell Lymphoma (DLBCL), previously untreated or relapsed/refractory Follicular Lymphoma (FL), and Chronic Lymphocytic Leukemia (CLL).
- Comprehensive Clinical Validation: Validated through rigorous multicenter randomized trials, achieving equivalent complete remission (CR) and overall response rates (ORR) when combined with standard CHOP regimens.
2. Premier Shanghai Hospitals & Oncology Teams Utilizing Henlius Biosimilars
Shanghai's leading tertiary teaching hospitals and comprehensive cancer centers have pioneered the clinical implementation, therapeutic monitoring, and pharmacoeconomic evaluation of Henlius biosimilars:
-
Shanghai Ruijin Hospital (Shanghai Jiao Tong University School of Medicine)
Department of Medical Oncology & State Key Laboratory of Medical Genomics: Ruijin’s breast cancer and hematology teams have conducted extensive real-world post-market surveillance on HLX02 and HLX01, validating identical long-term disease-free survival (DFS) and safety compared to originator biologics. -
Shanghai Zhongshan Hospital (Fudan University)
Department of Medical Oncology & Breast Surgery: Routinely integrates Henlius trastuzumab into neoadjuvant and adjuvant treatment pathways for HER2-positive breast malignancies and advanced gastric adenocarcinoma. -
Shanghai Renji Hospital (Shanghai Jiao Tong University School of Medicine)
Department of Oncology & Division of Hematology: Employs Henlius rituximab across high-volume outpatient chemotherapy units, establishing standardized infusion protocols and monitoring for low infusion-related reaction (IRR) profiles.
3. Procurement Advantages for Overseas Buyers & Health Authorities
- Proven Regulatory Track Record: Having successfully passed multiple stringent inspections by the European Medicines Agency (EMA) and qualified for EU national tenders, Henlius provides verified quality that mitigates regulatory risk for international procurement committees.
- Significant Budget Optimization: Offers 30%–50% cost reductions relative to originator reference biologics, enabling healthcare networks and national public health systems to significantly broaden patient access within capped pharmacy budgets.
- World-Scale Commercial Biomanufacturing: Produced at Henlius’s Songjiang and Xuhui facilities in Shanghai, featuring advanced single-use bioreactor systems and high-throughput automated filling lines that guarantee large-scale, uninterrupted batch supply.
- Validated 2°C–8°C Cold-Chain Supply Architecture: End-to-end temperature-monitored international air freight transit, ensuring zero cold-chain excursions between Shanghai manufacturing and destination port bonded warehouses.
4. How CMCS Assists Overseas Buyers with Commercial Navigation
Executing multi-market biosimilar distribution agreements or national health tender contracts requires on-ground verification of GMP manufacturing compliance, stability data review, and direct manufacturer engagement. CMCS provides an authoritative bridge in Shanghai:
- Clinical Real-World Data & KOL Dialogue: We coordinate peer-to-peer clinical exchanges for overseas chief medical officers and oncology hospital directors with leading Shanghai clinical investigators (e.g., at Ruijin and Zhongshan), reviewing hospital pharmacy formularies, efficacy data, and adverse event profiles.
- Songjiang Commercial Biologics Facility Audits: CMCS coordinates on-ground technical audits for international procurement delegations at Henlius’s Songjiang biomanufacturing campus, inspecting automated visual inspection lines, cold-chain storage hubs, and analytical QC laboratories.
- Direct Commercial & Tender Distribution Negotiations: We connect international buyers directly with Henlius’s global commercial leadership and licensed export pharmaceutical entities to negotiate direct-from-manufacturer supply contracts, distributor licensing, and tender support packages without intermediary markups.
- Licensed Pharmaceutical Logistics & Regulatory Dossier Support: We assist in coordinating compliant cold-chain customs clearance for Category D biopharmaceutical products through the Shanghai Free Trade Zone, aligning with licensed pharmaceutical freight forwarders to ensure uninterrupted 2°C–8°C data-logged transit.
Strict Regulatory & Compliance Boundary Notice
China Medical Concierge – Shanghai (CMCS) is an independent healthcare management and medical procurement navigation consultancy based in Shanghai. CMCS is NOT a licensed pharmaceutical trading company, pharmaceutical distributor, or pharmacy, and does NOT sell, distribute, export, or dispense prescription medications directly. Trastuzumab and Rituximab biosimilars are prescription biological products requiring licensed pharma-to-pharma transactions, valid Ministry of Health import licenses, and specialized pharmaceutical cold-chain handling. CMCS strictly facilitates professional on-ground technical audits, clinical exchanges, and direct commercial introductions to certified pharmaceutical manufacturers and their licensed export partners. CMCS does not support personal drug mailing or unlicensed cross-border pharmaceutical transfers.
Initiate a Biosimilar Procurement Consultation in Shanghai
To schedule an academic clinical review in Shanghai, coordinate a technical audit of Henlius's Songjiang biomanufacturing facility, or receive technical dossiers and commercial partnership information for Trastuzumab and Rituximab biosimilars, please contact our international liaison office:
- Email: contract@medicalsh.com
- WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
- Website: www.medicalsh.com
0 Kommentare